Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000950170-25-070358
Filing Date
2025-05-13
Accepted
2025-05-13 16:12:36
Documents
63
Period of Report
2025-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q antx-20250331.htm   iXBRL 10-Q 2155107
2 EX-10.1 antx-ex10_1.htm EX-10.1 42604
3 EX-31.1 antx-ex31_1.htm EX-31.1 18791
4 EX-31.2 antx-ex31_2.htm EX-31.2 19104
5 EX-32.1 antx-ex32_1.htm EX-32.1 9041
6 EX-32.2 antx-ex32_2.htm EX-32.2 8841
  Complete submission text file 0000950170-25-070358.txt   7677963

Data Files

Seq Description Document Type Size
7 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT antx-20250331.xsd EX-101.SCH 947474
66 EXTRACTED XBRL INSTANCE DOCUMENT antx-20250331_htm.xml XML 1231485
Mailing Address 1800 EL CAMINO REAL, SUITE D MENLO PARK CA 94027
Business Address 1800 EL CAMINO REAL, SUITE D MENLO PARK CA 94027 (650) 331-9090
AN2 Therapeutics, Inc. (Filer) CIK: 0001880438 (see all company filings)

EIN.: 820606654 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-41331 | Film No.: 25940236
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)